Frontline WSIB Workers Rally at Ford's Office Amid Growing Strike Tensions
TORONTO--(BUSINESS WIRE)-- #FordNation--Harry Goslin, President of the Ontario Compensation Employees Union (OCEU/CUPE 1750), will join striking Workplace Safety and Insurance Board (WSIB) workers on the picket line outside Premier Doug Ford's constituency office at 823 Albion Road in Etobicoke on Thursday, July 3, between 10:00 a.m. and 2:00 p.m. ET. This picket follows new revelations that WSIB has begun outsourcing core work performed by frontline union members, despite an ongoing province-wide strike now.
Frontline May Have Calmer Seas Ahead Of It
Frontline (FRO) remains a volatile but attractive long-term play, especially for investors able to stomach wild price swings and inconsistent dividends. Recent geopolitical improvements, especially the Iran-Israel ceasefire, should reduce shipping risks and costs, benefiting Frontline's operations and margins going forward. Despite a recent dividend cut and oil price risks, Frontline's high yield and potential for increased oil transport support a bullish long-term outlook.
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed among evaluable patients; safety profile remains strong Evidence mounts for mipletamig as a potentially transformational addition to standard of care in frontline AML as targeted CD123 x CD3 approach showing power and precision, limited added toxicity Mipletamig Trial Momentum Builds as Cohort 3 Nears Full Enrollment at highest dose level evaluated to date in combination therapy SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced new clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza) for newly diagnosed patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Across two trials, the mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients-which significantly exceeds results from competitor studies, including those achieved in the Viale A trial that evaluatedvenetoclax and azacitidine (ven/aza) as doublet therapy.
Verizon Frontline Network Slice now available nationwide
First responders in all major markets now have access to dedicated 5G UW network capacity First responders in all major markets now have access to dedicated 5G UW network capacity
Frontline Education Announces Jonathan Kost as Chief Strategy Officer
Wayne, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Wayne, Pa. – [June 12, 2025] –  Frontline Education, a leading provider of administration software purpose-built for educators in K-12, today announced Jonathan Kost as Chief Strategy Officer, a newly created position on the company's Executive Leadership Team. He will lead Frontline's strategic direction and innovation efforts to accelerate growth and advance the company's mission in K-12 education.
EdTech Breakthrough Awards Frontline HCM With 2025 “Education Administration Solution of the Year”
Prestigious International Awards Program Recognizes Outstanding Educational Technology Products and Companies Prestigious International Awards Program Recognizes Outstanding Educational Technology Products and Companies
Frontline plc (FRO) Q1 2025 Earnings Call Transcript
Frontline plc (FRO) Q1 2025 Earnings Call Transcript
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patients Completed 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicities No dose reductions required to the standard-of-care therapy with 40 mg and 80 mg TUS dose cohorts CSRC endorsed escalation to 120 mg TUS dosing First patient dosed with 120 mg TUS triplet and enrollment continues SAN DIEGO and TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that the Cohort Safety Review Committee (CSRC) monitoring Aptose's Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 80 mg dose TUS to 120 mg dose TUS based on its favorable review of safety and efficacy data from patients in the first two cohorts of the trial. Dosing of the first subject at the 120 mg TUS dose level has commenced.
Verizon welcomes Ericsson to the ranks of “Verizon Frontline Verified” partners
BASKING RIDGE, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Verizon Frontline today announced Ericsson Enterprise Wireless Solutions as the latest partner to earn “Verizon Frontline Verified” status.
Verizon Frontline Network Slice launches coast-to-coast
Dedicated 5G UW network capacity for first responders strengthens communications for public safety Dedicated 5G UW network capacity for first responders strengthens communications for public safety
Verizon announces Rescue 42 as latest “Verizon Frontline Verified” partner
BASKING RIDGE, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Verizon Frontline today announced Rescue 42 as the latest partner to earn “Verizon Frontline Verified” status.
Zoom Workplace for Frontline now available to improve on-shift communications and work management for frontline workers
SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Today, Zoom Communications, Inc. (NASDAQ: ZM), announced the launch of Zoom Workplace for Frontline, a purpose-built mobile-first solution that unlocks agentic Zoom AI Companion skills for all frontline workers and managers with paid Zoom accounts.
